Getinge has secured over 75 % of the outstanding shares in Pulsion ­and the transaction has been approved by German Federal Cartel Office

As earlier communicated, Getinge has issued a public tender offer to acquire all
shares in Pulsion Medical Systems SE (“Pulsion”) listed on the German Stock
Exchange (Deutsche Börse) for an offer price of € 16.90 per share in cash.

Getinge has now secured 76.88% of the outstanding shares and voting rights in
Pulsion, which corresponds to 6.342.945 shares. In addition, the German Federal
Cartel Office (Bundeskartellamt) has approved the transaction, today.

The board of Pulsion has recommended the Pulsion shareholders to accept the
public tender offer.

The acceptance period is still ongoing and will expire on 12 February 2014. The
transaction is expected to be completed in the first quarter of 2014.

Further conditions and information pertaining to the public tender offer are set
forth in the offer document and is available on www.maquet.com/pulsion-angebot.

For further information please contact:

Ulf Grunander
CFO, Getinge Group
Telefon: +46 10 335 55 80
E-post: ulf.grunander@getinge.com

Disclaimer

The public tender offer is inter alia subject to the condition that a minimum
acceptance threshold of at least 75% of the Pulsion shares (including shares
owned by the offeror and persons/companies acting jointly with the offeror) is
reached. The condition of the minimum acceptance threshold is defined in the
offer document to the effect, that the condition cannot be met before expiry of
the offer period. Thus, this condition has not yet been fulfilled even though
the current acceptance level exceeds 75%.

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and life
sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.
The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act